repaglinide + warfarin + omeprazole + Y-3-Neurodawn Pharmaceutical Co., Ltd.

repaglinide + warfarin + omeprazole + Y-3-Neurodawn Pharmaceutical Co., Ltd. is a drug combination regimen utilized in clinical pharmacology studies to evaluate the pharmacokinetic drug-drug interaction (DDI) potential of Y-3, an investigational small molecule developed by Neurodawn Pharmaceutical Co., Ltd. Y-3 is a dual-target therapeutic designed to disrupt the PSD95/nNOS interface and modulate GABA receptors, with primary indications in acute ischemic stroke and post-stroke depression. This specific regimen incorporates repaglinide, warfarin, and omeprazole as sensitive probe substrates for the cytochrome P450 enzymes CYP2C8, CYP2C9, and CYP2C19, respectively. By administering these agents alongside Y-3, researchers can assess whether Y-3 inhibits or induces these metabolic pathways, thereby informing safe co-administration guidelines and the drafting of drug instructions for Y-3 upon potential marketing.